142 related articles for article (PubMed ID: 17968747)
1. Design of population pharmacokinetic experiments using prior information.
Ogungbenro K; Aarons L
Xenobiotica; 2007; 37(10-11):1311-30. PubMed ID: 17968747
[TBL] [Abstract][Full Text] [Related]
2. A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models.
Graham G; Gueorguieva I; Dickens K
Comput Methods Programs Biomed; 2005 Jun; 78(3):237-49. PubMed ID: 15899308
[TBL] [Abstract][Full Text] [Related]
3. Optimal design of pharmacokinetic studies.
Aarons L; Ogungbenro K
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):250-5. PubMed ID: 20102362
[TBL] [Abstract][Full Text] [Related]
4. Application of optimal design methodologies in clinical pharmacology experiments.
Ogungbenro K; Dokoumetzidis A; Aarons L
Pharm Stat; 2009; 8(3):239-52. PubMed ID: 19009585
[TBL] [Abstract][Full Text] [Related]
5. POPED, a software for optimal experiment design in population kinetics.
Foracchia M; Hooker A; Vicini P; Ruggeri A
Comput Methods Programs Biomed; 2004 Apr; 74(1):29-46. PubMed ID: 14992824
[TBL] [Abstract][Full Text] [Related]
6. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
Bos AM; Boom K; Vinks AA; Boezen HM; Wanders J; Dombernovsky P; Aamdal S; de Vries EG; Uges DR
Cancer Chemother Pharmacol; 2004 Jul; 54(1):64-70. PubMed ID: 15069581
[TBL] [Abstract][Full Text] [Related]
7. Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.
Ogungbenro K; Graham G; Gueorguieva I; Aarons L
J Biopharm Stat; 2008; 18(2):342-58. PubMed ID: 18327725
[TBL] [Abstract][Full Text] [Related]
8. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
Retout S; Mentré F; Bruno R
Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
[TBL] [Abstract][Full Text] [Related]
9. Adaptive design optimization: a mutual information-based approach to model discrimination in cognitive science.
Cavagnaro DR; Myung JI; Pitt MA; Kujala JV
Neural Comput; 2010 Apr; 22(4):887-905. PubMed ID: 20028226
[TBL] [Abstract][Full Text] [Related]
10. Experiment design through dynamical characterisation of non-linear systems biology models utilising sparse grids.
Donahue MM; Buzzard GT; Rundell AE
IET Syst Biol; 2010 Jul; 4(4):249-62. PubMed ID: 20632775
[TBL] [Abstract][Full Text] [Related]
11. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.
Dokoumetzidis A; Aarons L
J Biopharm Stat; 2007; 17(5):851-67. PubMed ID: 17885870
[TBL] [Abstract][Full Text] [Related]
12. Bayesian experimental design for nonlinear mixed-effects models with application to HIV dynamics.
Han C; Chaloner K
Biometrics; 2004 Mar; 60(1):25-33. PubMed ID: 15032770
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics II: estimation methods.
Ette EI; Williams PJ
Ann Pharmacother; 2004 Nov; 38(11):1907-15. PubMed ID: 15367729
[TBL] [Abstract][Full Text] [Related]
14. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.
Retout S; Comets E; Samson A; Mentré F
Stat Med; 2007 Dec; 26(28):5162-79. PubMed ID: 17486667
[TBL] [Abstract][Full Text] [Related]
15. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
Bazzoli C; Retout S; Mentré F
Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
[TBL] [Abstract][Full Text] [Related]
16. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
[TBL] [Abstract][Full Text] [Related]
17. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
Foo LK; McGree J; Duffull S
Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the pre-posterior distribution of optimized sampling times for the design of pharmacokinetic studies.
Duffull SB; Graham G; Mengersen K; Eccleston J
J Biopharm Stat; 2012; 22(1):16-29. PubMed ID: 22204524
[TBL] [Abstract][Full Text] [Related]
19. The Taguchi methodology as a statistical tool for biotechnological applications: a critical appraisal.
Rao RS; Kumar CG; Prakasham RS; Hobbs PJ
Biotechnol J; 2008 Apr; 3(4):510-23. PubMed ID: 18320563
[TBL] [Abstract][Full Text] [Related]
20. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
Graham G; Aarons L
Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
